The government’s growing role in sponsoring research on comparative effectiveness of pharmaceutical treatments is triggering questions about how the resulting data and analytical methods will be viewed by FDA in its regulation of companies’ dissemination of such information.
Under the current statutory standard, health care economic information that is disseminated to formulary committees and similar entities must be based upon “competent and reliable scientific evidence.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?